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ABSTRACT: In the last few years, we have been witnessing an
increasing interest in ionic liquids (ILs) and organic salts, given their
potential applications in biological and pharmaceutical sciences. We
report the synthesis and in vitro evaluation of novel organic salts
combining betulinate, known for its anticancer properties, with
antimalarial drugs, primaquine, chloroquine, and mepacrine, and also
with the trihexyltetradecylphosphonium ([P6,6,6,14]) cation. The salts
were screened for their in vitro activity against tumor lines HepG2
(liver), MG63 (osteosarcoma), T47D (breast), A459 (lung), and
RKO (colon), and also on normal human fibroblasts. All betulinates
prepared displayed antiproliferative properties, with the trihexylte-
tradecylphosphonium betulinate standing out for its higher selectivity.
This unprecedented disclosure of a betulinic acid (BA)-derived IL
with selective antitumor activity constitutes a relevant first step toward
development of novel anticancer therapies based on BA-derived IL.
1. INTRODUCTION
Ionic Liquids (ILs) derived from active pharmaceutical
ingredients (API) may open new perspectives toward low-
cost rescuing or repurposing of classical drugs, given that most
available API are found in the cationic or anionic form.1−3
Therefore, the use of ILs has great potential to help the
pharmaceutical industry to overcome two of its most
concerning issues: solubility and polymorphism. In medicines,
API may be single- or multicomponent, such as, for example,
solvates (active + solvent), salts (active + counterion), or co-
crystals (active + crystal co-forming component), among
others.4,5 In the last two cases, as in any crystalline solid,
polymorphism may arise; and, even in solvated API pseudo-
polymorphism may occur. This means that distinct poly-
morphs may exhibit different properties that may influence
both the bioactivity and bioavailability of the drug. As such,
different therapeutic windows may be associated with distinct
polymorphic phases, which requires dose adjustment; more-
over, there is a risk of toxicity arising from the appearance of a
different undetected polymorphic phase that can cause harmful
effects to patients. This situation has led to product failures
and lengthy patent litigation.2,5−7 Whenever this kind of
problem appears, and because most drugs have at least one
ionizable functional group, the most common strategy is
formation of a salt of that drug, that is, conjugation of the drug
with a counterion as this represents, in most cases, an
improvement over the neutral drug. Thus, today, about 50% of
the drugs are administered as salts.2,8−11
The formation of organic salts, including ILs, derived from
API provides a simple tool to tune physical properties such as
thermal stability, crystallinity, hygroscopicity, water solubility,
and bioavailability. Thus, conversion of a neutral drug into a
convenient organic salt often results in improved physical,
chemical, and biological characteristics.5,9,12,13 One example is
that of antimalarial drugs, most of which are administered as
salts (e.g., primaquine (PQ) bisphosphate, chloroquine (CQ)
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bisphosphate, mepacrine (MP) hydrochloride, proguanil
hydrochloride, and sodium artesunate, among others).14,15 As
such, antimalarial API can be combined with either an inert
counterion or a counterion displaying additional biological
properties, eventually producing novel drug-derived ILs (API-
IL) with therapeutic interest. In this connection, and following
our long-term research focus in rescuing and repurposing
antimalarial drugs such as PQ, (1),16−22 CQ, (2),23,24 or MP,
(3)25−27 (Figure 1) we have recently developed PQ-derived
ILs with improved biological activity compared to the parent
compounds.28
Previous reports, both by us and by others, have highlighted
the potential of repurposing antimalarials for cancer.26,29−32
Some of the works recently conducted in this topic suggest
that, more than the intrinsic antiproliferative properties of the
antimalarials, it is their role as tumor cell sensitizers, able to
potentiate the therapeutic action of available antitumor drugs,
that makes them valuable tools to fight cancer.30,31 On the
basis of these reports, we reasoned that a combination of
classical antimalarials such as PQ, CQ, or MP with the
antitumoral compound betulinic acid (BA, 4 in Figure 2)
might produce organic salts with improved water solubility as
well as enhanced antiproliferative activity because of a possible
sensitization of cancer cells to BA.
The choice of BA, a triterpenoid that can be obtained from
renewable sources and displays a variety of biological
properties, namely, anti-inflammatory,38,39 anti-HIV,40,41 anti-
malarial,42,43 immunomodulatory,44,45 antiangiogenic,46,47 anti-
fibrotic,48,49 and hepatoprotective,50 was based on its reported
cytotoxicity to tumor cell lines such as lung, ovary, neuro-
blastoma, and glioblastoma. Moreover, BA has quite low water
solubility, so suitable formulations are needed to enable its
future valorization as an API; previous reports suggest that BA-
based organic cations and ILs may help to meet this goal, as
choline betulinate (5, Figure 2) was found be at least 100 times
more soluble in water than free BA.50−53
In view of the above, we pursued the chemical synthesis and
in vitro evaluation of the antiproliferative properties of PQ,
CQ, and MP betulinates. Trihexyltetradecylphosphonium
([P6,6,6,14]) betulinate was also produced, based on the long-
known anticancer potential of phosphonium salts.33−37 Hope-
fully, a combination of the betulinate anion with organic
cations, as the protonated forms of the aforementioned
antimalarial drugs or the trihexyltetradecylphosphonium
cation, might deliver organic salts with improved solubility,
and a synergetic effect against tumor cell lines.54 The target
organic salts were synthesized and evaluated in vitro for their
activity on one normal and five tumoral cell lines. The most
interesting compound was further tested for its effects on
important signaling pathways in cancer: the mitogen-activated
protein kinase/extracellular signal-regulated kinase (MAPK/
ERK, or simply MEK) pathway, the nuclear factor kappa-light-
chain-enhancer of activated B cells (NF-kB) pathway, and the
c-Jun N-terminal kinases (JNK) pathway.55−60
2. RESULTS AND DISCUSSION
2.1. Chemical Synthesis. There are two main methods for
the chemical synthesis of ILs and organic salts, namely,
metathesis and acid-base neutralization. While metathesis has
some issues regarding yield and purity of the target products,
acid-base neutralization is the “most intuitive” method, as it
rests on a basic principle of chemistry, which is the direct
neutralization of an acid with a base.1,55−58 Moreover, the
neutralization method is more advantageous for industrial
applications, as it can be easily implemented on a large
scale.1,59,60 As such, we have been successfully employing this
method for the synthesis of ILs and organic salts derived from
different API.1,28
The target organic salts derived from BA and the
antimalarial drugs [PQ][BA], [CQ][BA], and [MP][BA]
(Figure 3a) were thus synthesized by the neutralization
method, as previously reported,28 whereby each of the basic
antimalarials was reacted with an equimolar amount of BA.1,28
For the chemical synthesis of [P6,6,6,14][BA] (Figure 3b), the
commercially available chloride salt [P6,6,6,14][Cl] was con-
verted into the hydroxide, using an Amberlyst anion exchange
resin (A26-OH), prior to the neutralization reaction with BA.
These procedures delivered the target ionic compounds in
quantitative yields (Table 1) and free of detectable impurities,
as confirmed by high-resolution mass spectrometry (HRMS)
and by 1H and 13C NMR (see the Supporting Information).
An 1H NMR analysis confirmed the complete proton
transfer from BA to the basic building block, as the singlet at
12 ppm corresponding to the carboxylic proton in BA was not
observed for any of the salts prepared, as illustrated by Figure
4, where the 1H NMR spectra of AB, CQ, and [CQ][AB] in
the 12.5−4.0 ppm region are overlapped; this superposition
further shows an upfield shift of the vinylic protons in BA as a
result of the neutralization process. Moreover, the expected
cation/anion 1:1 ratio could be confirmed through a
quantitative integration of characteristic 1H resonance peaks
from nonionizable protons, namely, either of the vinylic
protons in betulinate (peaks at ca. 4.6 and 4.5 ppm, see Figure
4 and the Supporting Information) and either of the aromatic
protons (peaks in the 8.5−6.0 ppm interval, see Figure 4 and
the Supporting Information) in protonated PQ, CQ, or MP, or
the methylic protons (at ca. 0.9 ppm, integrating to 12
protons) from the trihexyltetradecylphosphonium cation (see
the Supporting Information).
Figure 1. Primaquine (PQ, 1), chloroquine (CQ, 2), and mepacrine
(MP, 3).
Figure 2. Structures of BA (4) and choline betulinate ([choline][BA],
5).
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Notably, as shown in Table 1, all but [P6,6,6,14][BA] were
solid at room temperature, evidencing relatively high melting
points, which were apparently accompanied by decomposition
(drastic change in compound color at the melting temper-
ature). In turn, [P6,6,6,14][BA] was a room-temperature IL.
2.2. Antiproliferative Activity in Vitro. Five tumor cell
lines (RKO, T47D, MG63, A549, and HepG2) were used to
evaluate the effects of the BA-derived salts on cell viability in
vitro. The compounds were tested at 0.5, 5, 50, and 500 μM,
and cell viability was determined by the 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) method at 24
and 72 h. Human fibroblasts (HFF-1) were also used to assess
compounds’ selectivity, and BA was included for reference. All
compounds displayed cytotoxic effects after 24 h, which were
retained after 72 h in most cases (see Table S1, Supporting
Information). The IL [P6,6,6,14][AB] had the most interesting
behavior after 72 h (Table 2), as it was the least toxic to HFF-1
cells, while being cytotoxic to the cancer cell lines, particularly
in the case of A549 (lung) and HepG2 (liver) cells. This holds
great promise, as salts of [P6,6,6,14] have been reported as
generally cytotoxic, in a nonselective fashion.61−63
2.3. Interference with Cellular Signaling Pathways.
Given the interesting behavior of the IL [P6,6,6,14][BA], its
effects on the modulation of three relevant intracellular
signaling pathways, MEK, NF-kB, and JNK, were further
investigated. The election of these particular signaling
pathways was based on their reported relevance in tumori-
genesis:61−66 the MEK pathway is fundamental for neoplastic
formation and development, and preclinical and laboratory
studies support it as a viable target for the therapy of some
types of cancer;61,62 NF-kB regulates the expression of genes
involved in many processes that appear to be critical for the
development and progression of cancer, such as proliferation,
migration, and apoptosis;63,64 moreover, previous works
suggest that BA might interfere with this pathway,44 and the
closely related Nrf2 pathway was recently found as relevant for
the response of A549 and HepG2 cells, on which
[P6,6,6,14][BA] was most active, to antitumoral compounds;
67
finally, the JNK signaling pathway, by being a regulator of
proinflammatory genes, tissue remodeling, and apoptosis,
constitutes an attractive target for new therapies in different
pathological contexts.65,66
The ability of [P6,6,6,14][BA] to modulate the aforemen-
tioned signaling pathways was tested in vitro after 24 and 72 h,
using suitable inhibitors of each of the pathways: U0126 for
MEK, PDTC for NF-kB, and SP600125 for JNK, and the
MTT method to assess cell viability (see Supporting
Figure 3. Synthetic route toward BA-derived organic salts, by
combination with (a) antimalarials and (b) [P6,6,6,14].
Table 1. Yields and Aspect of the Target Organic Salts
compound yield (%) physical state m.p.(dec)a/°C
[PQ][AB] 96.9 orange solid 170−175
[CQ][AB] 99.8 white solid 220−225
[MP][AB] 99.9 yellow solid 130−134
[P6,6,6,14][AB] 99.7 colorless liquid
aMelting point (with observable decomposition).
Figure 4. Superimposed 1H NMR spectra of BA (green), CQ (blue), and [CQ][BA] (brown). The carboxylic proton peak at ca. 12 ppm
exclusively observed for unmodified BA is missing in the spectrum of its [CQ][BA] salt, thus confirming the transfer of this proton to the basic
building block. Peaks associated to the BA’s vinylic protons further confirm changes because of the neutralization reaction, by being shifted upfield
in the salt, as compared to unmodified BA.
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Information, Table S2). Results obtained at 72 h are shown in
Table 3, and suggest that:
• in the absence of [P6,6,6,14][BA], fibroblasts seem
particularly dependent on the NF-kB pathway;
• addition of [P6,6,6,14][BA] to fibroblast cultures down-
regulates NF-kB and upregulates JNK;
• JNK appears to be an important pathway for RKO,
T47D, and HepG2 cells;
• upon addition of [P6,6,6,14][BA] to cancer cell cultures,
RKO and HepG2 cell lines appeared to become less
dependent on the JNK pathway, whereas T47D and
HepG2 exhibited an upregulated NF-kB pathway;
• the three pathways seem affected in T47D cells upon
addition of [P6,6,6,14][BA], but similar effects in the other
cancer cell lines are not evident.
Overall, this differential behavior of cell signaling responses
in fibroblasts as compared to, for example, HepG2, when
treated with [P6,6,6,14][AB], may underlie the cancer versus
normal cells’ selectivity presented by this IL. Still, this
preliminary assessment requires further investigation in order
to draw conclusive interpretations.
3. CONCLUDING REMARKS
The physico-chemical properties, and particularly the tuna-
bility of organic salts and ILs, are of great interest for drug
development.9,68 The pharmaceutical industry first looked at
ILs as “greener” alternates to solvents used in the synthesis of
API69 and, soon after, as potential co-adjuvants in drug
formulations.70−72 Upon discovery of bioactive organic salts,
including API-ILs, many new ILs were developed as potential
antineoplastic agents,36,73−78 and several known ones were
screened for their cytotoxicity to both normal and cancer cell
lines from different species13,53,79−85 Still, lack of sufficient
knowledge on the possible mechanisms of antitumor action of
ILs remains a major shortcoming toward rational design of
novel anticancer ILs.13 The present work represents initial, but
promising steps toward the understanding of the antineoplastic
potential of ILs and organic salts derived from a natural
antitumor compound. Remarkably, all organic salts synthesized
displayed antiproliferative activity in vitro, amongst which IL
[P6,6,6,14][AB] stood out for its selectivity, compared with all
the other organic salts and with the parent BA. A preliminary
investigation on cellular signaling pathways eventually
modulated by this IL did not show any marked trends; still,
it suggested a differential response of human fibroblasts to
[P6,6,6,14][AB], as compared to the other cell lines, which might
be related to the considerably lower toxicity of this IL to
normal cells, as compared to cancer ones.
We are aware that the antiproliferative activities displayed by
the BA-derived organic salts herein reported are not
extraordinary. However, the panel of tumor cells assayed is
still a small one, and subsequent studies shall include a larger
set of cancer cell lines, including drug-resistant ones. The same
applies to the signaling pathways potentially affected by the
test compounds, as a clearer picture on where these are
interfering will guide the future choice of alternative cationic
drugs to combine with BA in order to obtain more potent
antiproliferative activity. On the other hand, one cannot forget
that a major drawback in most anticancer therapies is the lack
of selectivity that characterizes most of the potent chemo-
therapeutic agents currently used in the clinics, which makes
the [P6,6,6,14][BA] IL herein reported a particularly relevant
therapeutic hit. Moreover, conversion of any therapeutic agent
that, like BA, is sparingly soluble in aqueous media, into
bioactive organic salts with significantly improved water
solubility, is by itself an important advance toward orally
bioavailable drugs. Hence, taken together, these findings
represent an important landmark toward future design and
development of new anticancer agents, based on low-cost
production of organic salts and ILs derived from antitumor
compounds.
Overall, these are encouraging and unprecedented results
disclosing the potential of BA-derived organic salts and ILs as a
new type of antitumor agents, which deserve further develop-
ment in the near future. Additional studies in this direction are
under way, and will be timely reported.
4. EXPERIMENTAL SECTION
4.1. General Materials and Methods. PQ biphosphate,
CQ phosphate, MP hydrochloride, BA, and tri-hexyltetrade-
cylphosphonhium chloride were acquired from Sigma-Aldrich.
Amberlyst A26-OH anion exchange resin was from Acros
Organics. NMR analyses were carried out on a Brucker
Table 2. IC50 Values (Mean ± SD, in μM) at 72 h, from Three Replicates in Three Independent Assays
compound HFF-1 RKO T47D MG63 A549 HepG2
BA 24.4 ± 0.8 17.7 ± 0.9 11.7 ± 0.8 11.7 ± 0.8 6.2 ± 0.8 16.1 ± 0.9
[CQ][BA] 12 ± 1 15 ± 1 15 ± 1 nd 10.1 ± 0.9 12.3 ± 0.9
[PQ][BA] 11 ± 1 13 ± 1 11.6 ± 0.9 6 ± 1 10 ± 1 13.0 ± 0.9
[MP][BA] nda nd 11 ± 1 5.3 ± 0.9 nd 4.1 ± 0.1
[P6,6,6,14][BA] 101.2 ± 0.2 60.5 ± 0.5 68.1 ± 0.4 nd 19 ± 1 16.8 ± 0.9
aConsistent IC50 values could not be determined.
Table 3. Viability (Mean ± SD, as %) at 72 h of Cells Supplemented with Signaling Pathway Inhibitors, in the Absence
(Control) or Presence of [P6,6,6,14][AB] at 50 μM
compound inhibitor HFF-1 RKO T47D MG63 A549 HepG2
control U0126 99 ± 2 88 ± 3 101.6 ± 0.8 116.6 ± 0.8 94.5 ± 0.8 98 ± 2
PDTC 58 ± 2 96 ± 3 94 ± 1 118.5 ± 0.9 88 ± 3 92 ± 1
SP600125 92 ± 3 57 ± 4 84.4 ± 0.7 92.1 ± 0.5 101 ± 2 72.8 ± 0.6
[P66614][AB] U0126 97.2 ± 0.3 115 ± 1 105.9 ± 0.4 99.1 ± 0.5 98.0 ± 0.1 83.2 ± 0.7
PDTC 80.4 ± 0.8 98.5 ± 0.9 80.2 ± 0.7 118.6 ± 0.4 131.0 ± 0.8 87.5 ± 0.6
SP600125 83 ± 1 87 ± 2 80.9 ± 0.3 166.4 ± 0.3 109.0 ± 0.4 69.4 ± 0.3
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AVANCE III 400 MHz spectrometer, and samples were
prepared in (CD3)2SO with tetramethylsilane as an internal
reference, from Euriso-Top. Chemical shifts are reported
downfield in parts per million (ppm). Mass spectra were
obtained on LTQ Orbitrap XL/LTQ Tune Plus 2.5.5/2.1.0
Xcalibur (Thermo Scientific) from methanolic (LC-MS grade,
from VWR international) solutions of the ILs, using electro-
spray ionization and ion trap detection (ESI−IT MS).
4.2. General Procedure for the Synthesis of the
Target Ionic Compounds. 4.2.1. Neutralization of the
Commercial Salts of the Antimalarial Drugs. The commer-
cial salt forms of PQ (bisphosphate), CQ (bisphosphate), and
MP (hydrochloride) were first converted into the respective
free amine bases. To this end, 30% aqueous sodium hydrogen
carbonate was added to the commercial antimalarial salt, and
the solution stirred for 15 min at room temperature, in the
dark. Formation of an oily layer was observed, and extracted
with dichloromethane (3 × 10 mL); the resulting organic layer
was then dried over anhydrous sodium sulfate, filtered, and the
filtrate evaporated to dryness under reduced pressure, to obtain
the free amine.
4.2.2. Formation of the Target Antimalarial-BA Salts by
Direct Acid-Base Neutralization. The antimalarial drug [as
free amine base, obtained according to section 4.2.1] was
dissolved in methanol; likewise, a methanolic solution of an
equimolar amount of BA was prepared in parallel. This
solution was then added dropwise to the methanolic solution
of the antimalarial drug, at room temperature and under
magnetic stirring. After 30 min, the solvent was evaporated,
and the residue dried under vacuum until constant weight.
This solid residue obtained was then analyzed by 1H- and 13C
NMR, and HRMS, and spectral data obtained were consistent
with the expected structures (see the Supporting Information).
4.2.3. Synthesis of [P6,6,6,14][BA]. Trihexyltetradecylphos-
phonium chloride was dissolved in methanol and passed
through an anion exchange column Amberlyst A-26(OH), (5.5
molar equivalents), and the resulting trihexyltetradecylphos-
phonium hydroxide solution was slowly added dropwise to a
methanolic solution of BA. The resulting mixture was stirred at
room temperature for 1 h, after which the solvent was
eliminated by evaporation under reduced pressure. The
resulting liquid residue was dried until constant weight, and
next analyzed by 1H- and 13C-NMR, and by HRMS, and
spectral data were consistent with the expected structure (see
the Supporting Information).
4.3. General Procedures for in Vitro Assays. The
organic salts synthesized were evaluated for their effect on
human cell viability. Different tumor cell lines were used,
namely, RKO, T47D, MG63, A549, and HepG2. In parallel,
HFF-1 human fibroblasts were used as a non-neoplastic
control, in order to assess the selectivity of the test ionic
compounds.
Cells were maintained in α-minimal essential medium
containing 10% fetal bovine serum, 100 IU/mL penicillin,
2.5 μg/mL streptomycin, 2.5 μg/mL amphotericin B, and 50
μg/mL ascorbic acid. Cells were seeded at 104 cells/cm2. After
24 h of cell attachment, the culture medium was renewed and
supplemented with different concentrations (0.5, 5, 50, and
500 μM) of the test compounds. Cell cultures were maintained
in a 5% CO2 humidified atmosphere at 37 °C. Cellular
viability/proliferation was assessed after 24 and 72 h, by the
MTT assay. This assay is based on the reduction of 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide to a
purple formazan product by viable cells. Half-maximal
inhibitory concentration (IC50) values were obtained by
nonlinear regression analysis of concentration−effect curves,
using GraphPad Prism software (version 2012).
In order to gather some insights about the intracellular
mechanisms affected by [P6,6,6,14][BA], cell cultures were
treated with this IL at 50 μM, and supplemented with different
commercial signaling pathway inhibitors, namely, U0126 (1
μM, MEK inhibitor), PDTC (10 μM, NF-kB inhibitor), and
SP600125 (10 μM, JNK inhibitor). Cell viability was assessed
by the MTT method, and the results were presented as a
percentage of the corresponding control (absence of the test
IL).
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Betulin as an Antitumor Agent Tested in vitro on A431, HeLa and
MCF7, and as an Angiogenic Inhibitor in vivo in the CAM Assay. Nat
Prod Commun 2012, 7, 981−985.
(47) Shin, J.; Lee, H. J.; Jung, D. B.; Jung, J. H.; Lee, E. O.; Lee, S.
G.; Shim, B. S.; Choi, S. H.; Ko, S. G.; Ahn, K. S.; Jeong, S. J.; Kim, S.
H. Suppression of STAT3 and HIF-1 Alpha Mediates Anti-
Angiogenic Activity of Betulinic Acid in Hypoxic PC-3 Prostate
Cancer Cells. PLoS One 2011, 6, e21492.
(48) Thakur, R.; Sharma, A.; Lingaraju, M. C.; Begum, J.; Kumar,
D.; Mathesh, K.; Kumar, P.; Singh, T. U.; Kumar, D. Ameliorative
effect of ursolic acid on renal fibrosis in adenine-induced chronic
kidney disease in rats. Biomed. Pharmacother. 2018, 101, 972−980.
(49) Wan, Y.; Wu, Y.-L.; Lian, L.-H.; Xie, W.-X.; Li, X.; OuYang, B.-
Q.; Bai, T.; Li, Q.; Yang, N.; Nan, J.-X. The anti-fibrotic effect of
betulinic acid is mediated through the inhibition of NF-kappa B
nuclear protein translocation. Chem.-Biol. Interact. 2012, 195, 215−
223.
(50) Harwansh, R. K.; Mukherjee, P. K.; Biswas, S. Nanoemulsion as
a novel carrier system for improvement of betulinic acid oral
bioavailability and hepatoprotective activity. J. Mol. Liq. 2017, 237,
361−371.
(51) Csuk, R. Betulinic acid and its derivatives: a patent review
(2008-2013). Expert Opin. Ther. Pat. 2014, 24, 913−923.
(52) Zhao, H.; Holmes, S. S.; Baker, G. A.; Challa, S.; Bose, H. S.;
Song, Z. Ionic derivatives of betulinic acid as novel HIV-1 protease
inhibitors. J. Enzyme Inhib. Med. Chem. 2012, 27, 715−721.
(53) Suresh, C.; Zhao, H.; Gumbs, A.; Chetty, C. S.; Bose, H. S.
New ionic derivatives of betulinic acid as highly potent anti-cancer
agents. Bioorg. Med. Chem. Lett. 2012, 22, 1734−1738.
(54) Egorova, K. S.; Seitkalieva, M. M.; Posvyatenko, A. V.;
Ananikov, V. P. An unexpected increase of toxicity of amino acid-
containing ionic liquids. Toxicol. Res. 2015, 4, 152−159.
(55) Ohno, H.; Fukumoto, K. Amino acid ionic liquids. Acc. Chem.
Res. 2007, 40, 1122−1129.
(56) Fukumoto, K.; Ohno, H. Design and synthesis of hydrophobic
and chiral anions from amino acids as precursor for functional ionic
liquids. Chem. Commun. 2006, 3081−3083.
(57) Florindo, C.; Costa, A.; Matos, C.; Nunes, S. L.; Matias, A. N.;
Duarte, C. M. M.; Rebelo, L. P. N.; Branco, L. C.; Marrucho, I. M.
Novel organic salts based on fluoroquinolone drugs: Synthesis,
bioavailability and toxicological profiles. Int. J. Pharm. 2014, 469,
179−189.
(58) Costa, A.; Forte, A.; Zalewska, K.; Tiago, G.; Petrovski, Z.;
Branco, L. C. Novel biocompatible ionic liquids based on gluconate
anion. Green Chem. Lett. Rev. 2014, 8, 8−12.
(59) Marrucho, I. M.; Branco, L. C.; Rebelo, L. P. N. Ionic Liquids
in Pharmaceutical Applications. Annu. Rev. Chem. Biomol. Eng. 2014,
5, 527−546.
(60) Fukumoto, K.; Yoshizawa, M.; Ohno, H. Room Temperature
Ionic Liquids from 20 Natural Amino Acids. J. Am. Chem. Soc. 2005,
127, 2398−2399.
(61) Grimaldi, A. M.; Simeone, E.; Festino, L.; Vanella, V.; Strudel,
M.; Ascierto, P. A. MEK Inhibitors in the Treatment of Metastatic
Melanoma and Solid Tumors. Am. J. Clin. Dermatol. 2017, 18, 745−
754.
(62) Shaul, Y. D.; Seger, R. The MEK/ERK cascade: From signaling
specificity to diverse functions. Biochim. Biophys. Acta Mol. Cell Res.
2007, 1773, 1213−1226.
(63) Ghosh, S.; Dass, J. F. P. Study of pathway cross-talk interactions
with NF-kappa B leading to its activation via ubiquitination or
phosphorylation: A brief review. Gene 2016, 584, 97−109.
(64) Dolcet, X.; Llobet, D.; Pallares, J.; Matias-Guiu, X. NF-kB in
development and progression of human cancer. Virchows Arch. 2005,
446, 475−482.
(65) Zhao, H.-F.; Wang, J.; To, S.-S. T. The phosphatidylinositol 3-
kinase/Akt and c-Jun N-terminal kinase signaling in cancer: Alliance
or contradiction? Int. J. Oncol. 2015, 47, 429−436.
(66) Bennett, B. L. N-terminal kinase-dependent mechanisms in
respiratory disease. Eur. Respir. J. 2006, 28, 651−661.
(67) Zhang, H.X.; Chen, Y.; Xu, R.; He, Q.Y. Nrf2 mediates the
resistance of human A549 and HepG2 cancer cells to boningmycin, a
new antitumor antibiotic, in vitro through regulation of glutathione
levels. Acta Pharmacol. Sin. 2018, 39, 1661−1669.
(68) Shamshina, J. L.; Kelley, S. P.; Gurau, G.; Rogers, R. D.
Chemistry: Develop ionic liquid drugs. Nature 2015, 528, 188−189.
(69) Earle, M. J.; Seddon, K. R. Ionic liquids. Green solvents for the
future. Pure Appl. Chem. 2000, 72, 1391−1398.
(70) Zavgorodnya, O.; Shamshina, J. L.; Mittenthal, M.; McCrary, P.
D.; Rachiero, G. P.; Titi, H. M.; Rogers, R. D. Polyethylene glycol
derivatization of the non-active ion in active pharmaceutical
ingredient ionic liquids enhances transdermal delivery. New J. Chem.
2017, 41, 1499−1508.
(71) Cojocaru, O. A.; Bica, K.; Gurau, G.; Narita, A.; McCrary, P.
D.; Shamshina, J. L.; Barber, P. S.; Rogers, R. D. Prodrug ionic liquids:
functionalizing neutral active pharmaceutical ingredients to take
advantage of the ionic liquid form. MedChemComm 2013, 4, 559−
563.
(72) McCrary, P. D.; Beasley, P. A.; Gurau, G.; Narita, A.; Barber, P.
S.; Cojocaru, O. A.; Rogers, R. D. Drug specific, tuning of an ionic
liquid’s hydrophilic-lipophilic balance to improve water solubility of
poorly soluble active pharmaceutical ingredients. New J. Chem. 2013,
37, 2196−2202.
(73) Dias, A. R.; Costa-Rodrigues, J.; Fernandes, M. H.; Ferraz, R.;
Prude ̂ncio, C. The Anticancer Potential of Ionic Liquids.
ChemMedChem 2017, 12, 11−18.
(74) Ferraz, R.; Costa-Rodrigues, J.; Fernandes, M. H.; Santos, M.
M.; Marrucho, I. M.; Rebelo, L. P. N.; Pruden̂cio, C.; Noronha, J. P.;
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